BRCA1 and pancreatic neoplasm: A PARP inhibitor, olaparib (Ola), is also indicated for treating patients with advanced pancreatic cancer with loss-of-function mutations in the germline BRCA1/2 gene and remaining sensitivity to the platinum-based anticancer drugs (10).